Skip to Content
Merck
All Photos(1)

Key Documents

203391

Sigma-Aldrich

(-)-Blebbistatin

≥98% (HPLC), solid, ATPase inhibitor, Calbiochem®

Synonym(s):

(-)-Blebbistatin

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C18H16N2O2
CAS Number:
Molecular Weight:
292.33
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

product name

(-)-Blebbistatin, The active enantiomer of (±)-Blebbistatin that accounts for the inhibitory activity towards ATPase and myosin II-dependent cellular processes.

Quality Level

Assay

≥98% (HPLC)

form

solid

potency

2 μM IC50

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

yellow

solubility

methanol: 1.5 mg/mL
100% DMSO: 100 mg/mL
90% DMSO: 75 mg/mL

shipped in

wet ice

storage temp.

−20°C

InChI

1S/C18H16N2O2/c1-12-7-8-15-14(11-12)16(21)18(22)9-10-20(17(18)19-15)13-5-3-2-4-6-13/h2-8,11,22H,9-10H2,1H3/t18-/m1/s1

InChI key

LZAXPYOBKSJSEX-GOSISDBHSA-N

General description

The active enantiomer of (±)-Blebbistatin (Cat. No. 203390) that accounts for the inhibitory activity towards ATPase (IC50 = ~2 µM) and myosin II-dependent cellular processes. Also reported to potently inhibit the actomyosin ATPase activities of expressed smooth muscle myosin IIA (SMA) and smooth muscle myosin IIB (SMB) smooth muscle myosin II heavy-chain isoforms (IC50 ~3 µM).
The active enantiomer of (±)-Blebbistatin (Cat. No. 203390) that accounts for the inhibitory activity toward ATPase (IC50 ~2 µM) and myosin II-dependent cellular processes. Also reported to potently inhibit the actomyosin ATPase activities of expressed smooth muscle myosin IIA (SMA) and smooth muscle myosin IIB (SMB) smooth muscle myosin II heavy-chain isoforms (IC50 ~3 µM).

Biochem/physiol Actions

Cell permeable: no
Product does not compete with ATP.
Reversible: no

Packaging

Packaged under inert gas

Warning

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month in 90% DMSO or methanol (-20°C). Stock solutions in 100% DMSO are unstable; reconstitute just prior to use.

Other Notes

Eddinger, T.J. et al. 2007. J. Pharmacol. Exp. Ther.320, 865.
Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003. Science299, 1743.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrew D Doyle et al.
Developmental cell, 56(6), 826-841 (2021-03-12)
We describe a cellular contractile mechanism employed by fibroblasts and mesenchymal cancer cells to migrate in 3D collagen gels. During 3D spreading, fibroblasts strongly deform the matrix. They protrude, polarize, and initiate migration in the direction of highest extracellular matrix
Dennis J Yuan et al.
Biomaterials, 273, 120797-120797 (2021-04-21)
T cell activation is sensitive to the mechanical properties of an activating substrate. However, there are also contrasting results on how substrate stiffness affects T cell activation, including differences between T cells of mouse and human origin. Towards reconciling these
Cell clusters adopt a collective amoeboid mode of migration in confined nonadhesive environments.
Pag??s, et al.
Science Advances, 8, eabp8416-eabp8416 (2022)
Adam Germain et al.
Oncology, 102(6), 515-524 (2023-11-27)
Cancers in general, and specifically lung cancer, continue to have low patient survival rates when the patient is at an advanced stage when diagnosed. It appears that the local environment, especially fibroblasts and their signaling molecules, tends to induce metastasis
Charlotte Canet-Jourdan et al.
Journal of cell science, 135(14) (2022-06-16)
The metastatic progression of cancer remains a major issue in patient treatment. However, the molecular and cellular mechanisms underlying this process remain unclear. Here, we use primary explants and organoids from patients harboring mucinous colorectal carcinoma (MUC CRC), a poor-prognosis

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service